Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

PURPOSE: To explore the potential factors impacting the efficacy of venlafaxine extended release (ER) and treatment differences between 75 mg/day and 75–225 mg/day dose in patients with major depressive disorder (MDD). METHODS: We performed exploratory post hoc subgroup analyses of a randomized, dou...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Yoshinori, Asami, Yuko, Hirano, Yoko, Kuribayashi, Kazuhiko, Itamura, Rio, Imaeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962303/
https://www.ncbi.nlm.nih.gov/pubmed/29844674
http://dx.doi.org/10.2147/NDT.S146428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962303/
https://www.ncbi.nlm.nih.gov/pubmed/29844674
http://dx.doi.org/10.2147/NDT.S146428

Ejemplares similares